Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
This is a phase I/II open label, multi-center study of azacytidine in combination with
standard RCHOP therapy in patients with DLBCL. Patients will be treated with azacytidine at
escalating doses on days 1-5, followed by standard dose rituximab plus CHOP chemotherapy on
day 8, every 21 days. Patients will be treated for a total 6 cycles. The phase II portion
will then evaluate efficacy of the combination at the established MTD.